Discussion  by unknown
type of AVR employed.7 The maximum follow-up in that
series was only 21 months, however, and this may have
limited the opportunity to observe important differences.
The primary limitation of this study is the heterogeneity
of the patients and the greater complexity of the allograft
group. The very need for the use of the allograft, in a
practice in which the Ross procedure is preferred, is evi-
dence of a more difficult to manage subgroup of patients.
More rigidly controlled studies of autografts versus allo-
grafts are unlikely to be conducted. It is highly improbable
that a randomized trial would be considered ethically justi-
fiable in a pediatric population, given the considerable the-
oretical and proven advantages of the autograft. Other lim-
itations of this study include the unavoidable problems of
patient numbers and follow-up duration and completeness.
Offsetting these limitations is the routine use of human
valves in nearly all patients, with a less than 4% frequency
of mechanical valve use over an extended period of time.
Another value of this study is the series of detailed, sequen-
tial echocardiographic studies that permitted the detection
of subtle changes in left ventricular physiology and mor-
phology.
Whether the echocardiographic observations in this
study are harbingers of future clinical events is unknown. It
is generally accepted that reduction in left ventricular mass
is a desirable goal. Resolution of ventricular hypertrophy is
a slow and steady process that eventually produces im-
provement in objective measures of ventricular function and
symptomatic status.10-12 Conversely, failure to resolve ven-
tricular hypertrophy is associated with a lesser improvement
in symptoms and functional measurements as well as in-
creased risk of death.13-15 It is logical to conclude that a
more rapid and complete resolution of ventricular hypertro-
phy should be a factor in the type of aortic valve replace-
ment device that a surgeon selects.16
The existing literature combined with the favorable find-
ings in this study thus should support the confident use of
the allograft for pediatric patients when the autograft is not
an option. At the same time, this study should encourage the
use of the autograft AVR in children whenever possible
both to achieve the maximum hemodynamic benefits for the
myocardium and to favorably influence longer-term clinical
events.
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Discussion
Dr John A. Hawkins (Salt Lake City, Utah). Mark, first I
commend you and your colleagues on excellent results obtained in
this very difficult group of patients. Basically Dr Lupinetti and Dr
Duncan and their colleagues have reported a large series of chil-
dren undergoing AVR with both autografts and allografts, with
only a 3% operative mortality and a single late death and an
acceptable level of late morbidity. These are really admirable
numbers for a complex group of patients dating from what I would
assume is your first Ross procedure in 1994. From the outset I will
have to say I am really a true believer in the Ross procedure and
have no arguments with your approach. I would summarize your
message this morning as basically, do a Ross procedure when you
can and an allograft when you cannot. The significant findings you
showed us today were that the left ventricular outflow tract Vmax
basically increased in allografts and significantly decreased in the
autograft group, while left ventricular posterior wall thickness
decreased significantly in the autograft group and remained un-
changed in the allograft group.
My first question has to do with the finding in your series of this
significant increase in the Doppler-measured Vmax across the left
ventricular outflow tract. What was the follow-up in both groups of
patients? You stated that the follow-up was simply 1 to 80 months.
What is the problem with the allografts developing this late gra-
dient? Is it simply a time-related or growth phenomenon rather
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than a problem with the allograft per se? In other words, were the
allograft patients simply observed longer and the finding was a
result of lack of growth of the allograft itself rather than a problem
with it alone?
Dr Lupinetti. The mean follow-up was 38 months for the Ross
procedure patients and 40 for the allograft, no statistically signif-
icant difference. Also, the completeness of follow-up was exactly
the same, 89% in each group, and each group had similar 12% to
13% incidence of being lost to follow-up. We could not attribute
any differences in our echo observations to time-related phenom-
ena.
Dr Hawkins. Do you think that 40 months is enough time in
the allograft group for these patients to grow significantly, to
perhaps produce the gradient because they are simply not grow-
ing?
Dr Lupinetti. That would be a difficult thing to determine
given the heterogeneous patient age and size, but it does seem to
be enough to evoke some change in allograft physiology that we
think is the most likely explanation for this.
Dr Hawkins. My second question has to do with the use of
posterior wall thickness as a measure of left ventricular hypertro-
phy. Why did you not use left ventricular mass, which is an
indexed measurement and probably a more accurate measure of
left ventricular hypertrophy, particularly over the wide range of
patient ages and sizes that you examined? Your weights ranged
from 3.6 kg all the way up to 130 kg and your ages ranged from
as young as about 2 months all the way up to 22 years. Would this
perhaps have been a better measurement of left ventricular hyper-
trophy rather than posterior wall thickness?
Dr Lupinetti. I agree. Left ventricular wall mass would have
been a superior method of following the echoes. Unfortunately,
although our clinical data were recorded prospectively and con-
currently, our echo study was purely retrospective. Having to deal
with a wide variety of echocardiographic techniques and a wide
variety of echocardiographers and cardiologists over this time
precluded the use of that. Instead, we had to go with the most
consistent reproducible measurement that we had, which was
posterior wall thickness.
Dr Hawkins. Last, inherent in any retrospective study is the
inability to have truly comparative groups. Your autograft group
tended to have mostly, if not solely, congenital aortic stenosis as
their original disease as compared with the allograft group, which
had a pretty diverse group of congenital defects such as truncus,
Marfan syndrome, tetralogy, or some previous operation that de-
stroyed the pulmonary valve. Do these differences in patient dis-
ease perhaps lead to the allograft patients having a worse hemo-
dynamic result rather than the use of the allograft itself?
Dr Lupinetti. I think it almost certainly does. I think it is
unquestioned that the quality of valve performance can be closely
related to the condition of patient in whom the valve is implanted.
I think what is remarkable about the allograft group is not that the
hemodynamic performance was a little bit worse but that the
clinical performance was perhaps as good as it was. I think there
is no question that the allografts were biased against by the nature
of the underlying disease.
Dr Edward Verrier (Seattle, Wash). My question concerns the
deterioration of an allograft. In many adults receiving allografts for
endocarditis, the valves deteriorate not only by calcification of the
valve but the entire prosthetic root so that the reoperation is
extraordinarily complex and potentially dangerous. We know that
even in pulmonary allografts used in the right ventricular–pulmo-
nary artery position, the primary mode of deterioration has to do
with calcification, although it is a much easier replacement. Have
you noticed an accelerated degeneration of the allografts with
calcification and have you had to reoperate on any of those that
have been technically challenging in this younger group of pa-
tients?
Dr Lupinetti. You mean reoperating on the allograft in the
Ross procedure?
Dr Verrier. No, not in the Ross procedure. It is the allograft in
the aortic position that worries me the most. When allografts
deteriorate and calcify and you reoperate, where you have coro-
nary buttons in place, a root that is calcified, and an aortic valve
that is calcified, that reoperation is very difficult. Having done this
now recently this past year in 3 patients, all in their 20s, I found it
extremely anxiety producing and a difficult challenge because I
had to remove the entire root.
Dr Lupinetti. We did have to reoperate on 3 of the aortic
allograft replacement patients. In 2 of those we were able to
replace it with another allograft. In the third patient who had
Marfan syndrome, the progressive dilatation of the root prohibited
us from implanting another allograft; we used a composite me-
chanical valve and ascending aortic graft in that patient.
Dr Mark Metzdorff (Portland, Ore). I note 4% mortality in
the Ross group and no mortality in the allograft group, which
seems to be a more difficult set of patients to treat. Was the higher
mortality significant and what were the reasons for the mortality?
Dr Lupinetti. Of the 3 patients who died, there was 1 patient
who was initially treated with a balloon aortic valvotomy, with a
rather hypoplastic left heart, and who returned at about a year of
age with pulmonary hypertension due to restrictive left ventricular
physiology. That patient underwent a Ross procedure but contin-
ued to have pulmonary hypertension and ultimately died of that. I
do not think the nature of the valve replacement really had a
material influence on how that patient would have done. The
second patient died of hemorrhage, a simple technical problem that
should not have been related to the type of valve replacement. The
third patient had a diminutive aortic root that would have normally
required a Kono procedure but the Kono could not be performed
because of abnormal coronary anatomy. That patient was left with
severe left ventricular outflow tract obstruction and ultimately died
of left ventricular failure. It is hard to say that we could have made
a material difference by our choice of valve, but as you say the
allograft group was the higher risk, higher complexity group, and
yet did quite well clinically.
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